Poniard Pharmaceuticals, Inc. (PARD)

Market Cap	15.00 -100.0%
Revenue (ttm)	n/a
Net Income	-16.23M
EPS	-3.79
Shares Out	1.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,103
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	-64.57
RSI	40.38
Earnings Date	n/a

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1984
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: PARD